Stac2-U-domain peptide is a 22-residue synthetic peptide that inhibits the Ca2+- dependent inactivation of Cav1.2 (cardiac L-type Ca2+-channel, dihydropyridine receptor), Cav1.3s and Cav1.4(43) (1). This results in an elongated action potential, and recapitulates features of longQT syndrome in ventricular myocytes from guinea pig (1). The peptide is derived from the sequence of human STAC2, which is expressed in the heart, delivers the longQT-like phenotype when presented to the cytoplasm of cardiac myocytes.
Synthetic peptide, sequence Ac- 200KVDPVYETLRYGTSLALMNRSS221-NH2, s derived from the sequence of human STAC2 . Formula weight 2541.9 : Acetylated N-terminus, amidated C-terminus, trifluoroacetate counter ions.
98% pure (HPLC reverse phase C18 column 100A 4.6 x 150mm column, gradient from 0% – 80% acetonitrile, in 15 minutes. 60 degC). Off white powdered solid.
1 mg weight
Dimethyl sulfoxide (DMSO), use minimum volume (10 µL) plus water to desired volume and peptide concentration.
Store desiccated at -20°C for up to 1 year in solid form. Dissolve in DMSO immediately before use in experiments. Stability in solution not known.
Product for research use only. Not intended for diagnostic or therapeutic use.